2026 Q2 -tulosraportti
20 päivää sitten
‧1 t 2 min
0,4078 USD/osake
Viimeisin osinko
2,63%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
22 t sittenTHE WOODLANDS, Texas, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has earned a third $10 million milestone payment in 2026 from Novo Nordisk A/S following the achievement of a key patient dosing milestone in the ongoing Phase 1 clinical development program for LX9851, a first-in-class oral small molecule inhibitor of ACSL5 being developed for obesity and associated metabolic disorders. LX9851 is being advanced by Novo Nordisk under the companies' exclusive worldwide license agreement signed in 2025. Under the terms of the agreement, Novo Nordisk obtained an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications. With the achievement of this milestone, Lexicon has now earned $75 million of the $1 billion in potential upfront, development, regulatory and commercial milestone payments available under its collaboration with Novo Nordisk. In addition, Lexicon is entitled to receive tiered royalties on future net sales of LX9851. “This milestone represents another important step forward in the development of LX9851 and further demonstrates the strong execution of our collaboration with Novo Nordisk,” said Mike Exton, CEO and director of Lexicon. “In just over a year, the program has progressed from a licensing agreement to the successful achievement of multiple clinical development milestones. We believe LX9851's novel mechanism and oral profile have the potential to offer an important new approach for people living with obesity and associated metabolic diseases, and we remain excited about the program's continued advancement." The Phase 1 development program for LX9851 was initiated by Novo Nordisk in March 2026 and is investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of LX9851 compared to placebo in adult subjects who are overweight or obese. The Phase 1 program is expected to be completed in the first quarter of 2027.
·19.8.Sold my half a million in Novo, moved them to SanDisk, immediately got a gain of 29 percent. In just 3 days, I did lose 3 percent on novo, but my portfolio became more valuable. So now I can buy Novo with my profit, when it reaches the right level to buy again. Good luck to you all. May we all get something in the account
·17.8.I'm still holding onto my belief in Novo. Not because I think the stock will suddenly explode upwards, but because I still believe the company holds some of the strongest cards in hand within obesity and diabetes. Yes, the share price has taken a beating, and yes, there's more competition, but that doesn't change Novo's many years of research, strong products, know-how, and global position overnight. What I especially try to avoid is letting myself be influenced by all the profiles who constantly talk Novo down. Some of them don't even own the stock. Of course, it's perfectly fair to be critical, but I'd much rather listen to facts, results, and the company's development than to people who create fear and drama. I'm not buying Novo because the stock is popular right now. I'm buying it because I believe in the company in the long term. For me, the question is therefore not why Novo is falling right now, but where Novo will stand in 3-5 years if they continue to develop new treatments and gain market share. I still believe there's a lot of potential. You don't have to agree with me, but I'd rather stick to my own analysis than let myself be scared by people who shout the loudest. Novo will come back 📈
·12.8. · MuokattuI really can't understand why there isn't more focus on Awiqli and that it's now being sold in the USA.. It seems like everything is now about fat percentages.. I asked AI: Awiqli from Novo Nordisk is the world's first weekly basal insulin. The active substance in the medicine is called insulin icodec. The drug is designed to replace traditional long-acting insulins, which patients normally have to inject themselves with every single day. Important details about Awiqli. Fewer injections: With the new drug, the number of annual insulin injections is significantly reduced from 365 to 52 injections per year. Target group: It is primarily approved for adults with type 2 diabetes. For type 1 diabetes, it must always be combined with rapid-acting mealtime insulin. Effect: The insulin is released slowly and steadily into the body over seven days because the molecule binds to the protein albumin in the blood.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
20 päivää sitten
‧1 t 2 min
0,4078 USD/osake
Viimeisin osinko
2,63%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 22 t sittenTHE WOODLANDS, Texas, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has earned a third $10 million milestone payment in 2026 from Novo Nordisk A/S following the achievement of a key patient dosing milestone in the ongoing Phase 1 clinical development program for LX9851, a first-in-class oral small molecule inhibitor of ACSL5 being developed for obesity and associated metabolic disorders. LX9851 is being advanced by Novo Nordisk under the companies' exclusive worldwide license agreement signed in 2025. Under the terms of the agreement, Novo Nordisk obtained an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications. With the achievement of this milestone, Lexicon has now earned $75 million of the $1 billion in potential upfront, development, regulatory and commercial milestone payments available under its collaboration with Novo Nordisk. In addition, Lexicon is entitled to receive tiered royalties on future net sales of LX9851. “This milestone represents another important step forward in the development of LX9851 and further demonstrates the strong execution of our collaboration with Novo Nordisk,” said Mike Exton, CEO and director of Lexicon. “In just over a year, the program has progressed from a licensing agreement to the successful achievement of multiple clinical development milestones. We believe LX9851's novel mechanism and oral profile have the potential to offer an important new approach for people living with obesity and associated metabolic diseases, and we remain excited about the program's continued advancement." The Phase 1 development program for LX9851 was initiated by Novo Nordisk in March 2026 and is investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of LX9851 compared to placebo in adult subjects who are overweight or obese. The Phase 1 program is expected to be completed in the first quarter of 2027.
- ·19.8.Sold my half a million in Novo, moved them to SanDisk, immediately got a gain of 29 percent. In just 3 days, I did lose 3 percent on novo, but my portfolio became more valuable. So now I can buy Novo with my profit, when it reaches the right level to buy again. Good luck to you all. May we all get something in the account
- ·17.8.I'm still holding onto my belief in Novo. Not because I think the stock will suddenly explode upwards, but because I still believe the company holds some of the strongest cards in hand within obesity and diabetes. Yes, the share price has taken a beating, and yes, there's more competition, but that doesn't change Novo's many years of research, strong products, know-how, and global position overnight. What I especially try to avoid is letting myself be influenced by all the profiles who constantly talk Novo down. Some of them don't even own the stock. Of course, it's perfectly fair to be critical, but I'd much rather listen to facts, results, and the company's development than to people who create fear and drama. I'm not buying Novo because the stock is popular right now. I'm buying it because I believe in the company in the long term. For me, the question is therefore not why Novo is falling right now, but where Novo will stand in 3-5 years if they continue to develop new treatments and gain market share. I still believe there's a lot of potential. You don't have to agree with me, but I'd rather stick to my own analysis than let myself be scared by people who shout the loudest. Novo will come back 📈
- ·12.8. · MuokattuI really can't understand why there isn't more focus on Awiqli and that it's now being sold in the USA.. It seems like everything is now about fat percentages.. I asked AI: Awiqli from Novo Nordisk is the world's first weekly basal insulin. The active substance in the medicine is called insulin icodec. The drug is designed to replace traditional long-acting insulins, which patients normally have to inject themselves with every single day. Important details about Awiqli. Fewer injections: With the new drug, the number of annual insulin injections is significantly reduced from 365 to 52 injections per year. Target group: It is primarily approved for adults with type 2 diabetes. For type 1 diabetes, it must always be combined with rapid-acting mealtime insulin. Effect: The insulin is released slowly and steadily into the body over seven days because the molecule binds to the protein albumin in the blood.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
2026 Q2 -tulosraportti
20 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
0,4078 USD/osake
Viimeisin osinko
2,63%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 22 t sittenTHE WOODLANDS, Texas, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has earned a third $10 million milestone payment in 2026 from Novo Nordisk A/S following the achievement of a key patient dosing milestone in the ongoing Phase 1 clinical development program for LX9851, a first-in-class oral small molecule inhibitor of ACSL5 being developed for obesity and associated metabolic disorders. LX9851 is being advanced by Novo Nordisk under the companies' exclusive worldwide license agreement signed in 2025. Under the terms of the agreement, Novo Nordisk obtained an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications. With the achievement of this milestone, Lexicon has now earned $75 million of the $1 billion in potential upfront, development, regulatory and commercial milestone payments available under its collaboration with Novo Nordisk. In addition, Lexicon is entitled to receive tiered royalties on future net sales of LX9851. “This milestone represents another important step forward in the development of LX9851 and further demonstrates the strong execution of our collaboration with Novo Nordisk,” said Mike Exton, CEO and director of Lexicon. “In just over a year, the program has progressed from a licensing agreement to the successful achievement of multiple clinical development milestones. We believe LX9851's novel mechanism and oral profile have the potential to offer an important new approach for people living with obesity and associated metabolic diseases, and we remain excited about the program's continued advancement." The Phase 1 development program for LX9851 was initiated by Novo Nordisk in March 2026 and is investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of LX9851 compared to placebo in adult subjects who are overweight or obese. The Phase 1 program is expected to be completed in the first quarter of 2027.
- ·19.8.Sold my half a million in Novo, moved them to SanDisk, immediately got a gain of 29 percent. In just 3 days, I did lose 3 percent on novo, but my portfolio became more valuable. So now I can buy Novo with my profit, when it reaches the right level to buy again. Good luck to you all. May we all get something in the account
- ·17.8.I'm still holding onto my belief in Novo. Not because I think the stock will suddenly explode upwards, but because I still believe the company holds some of the strongest cards in hand within obesity and diabetes. Yes, the share price has taken a beating, and yes, there's more competition, but that doesn't change Novo's many years of research, strong products, know-how, and global position overnight. What I especially try to avoid is letting myself be influenced by all the profiles who constantly talk Novo down. Some of them don't even own the stock. Of course, it's perfectly fair to be critical, but I'd much rather listen to facts, results, and the company's development than to people who create fear and drama. I'm not buying Novo because the stock is popular right now. I'm buying it because I believe in the company in the long term. For me, the question is therefore not why Novo is falling right now, but where Novo will stand in 3-5 years if they continue to develop new treatments and gain market share. I still believe there's a lot of potential. You don't have to agree with me, but I'd rather stick to my own analysis than let myself be scared by people who shout the loudest. Novo will come back 📈
- ·12.8. · MuokattuI really can't understand why there isn't more focus on Awiqli and that it's now being sold in the USA.. It seems like everything is now about fat percentages.. I asked AI: Awiqli from Novo Nordisk is the world's first weekly basal insulin. The active substance in the medicine is called insulin icodec. The drug is designed to replace traditional long-acting insulins, which patients normally have to inject themselves with every single day. Important details about Awiqli. Fewer injections: With the new drug, the number of annual insulin injections is significantly reduced from 365 to 52 injections per year. Target group: It is primarily approved for adults with type 2 diabetes. For type 1 diabetes, it must always be combined with rapid-acting mealtime insulin. Effect: The insulin is released slowly and steadily into the body over seven days because the molecule binds to the protein albumin in the blood.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt